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Safety and Efficacy of a New Regimen of Intravenous Recombinant
Tissue-Type Plasminogen Activator Potentially Suitable for Either
Prehospital or In-Hospital Administration
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THOMAS M. DREW . MD, FACC . FREDERICK FEIT, MD, FACC,t* BARRY L . SHARAF, MD,
EDWARD S . THOMAS, MD, FACC. SAM TEICHMAN, MD,t MARY JANE McDONALD, RN,
DAVID O . WILLIAMS, MD
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The safety and efficacy of a new regimen of intravenous recombi-
nant tissue-type plasminogen activator (ri-PA) potentially suitable
for either pre . or in-hospital administration were assessed in 60
patients with acute myocardial infarction in an open label coro-
nary angiographic study. The regimen consisted of a 20-mg bolus
dose followed 30 min later by a delayed infusion of 80 mg over
2 h
. This regimen was designed to facilitate prehospital adminis .
tratian of rt-PA,
lnfarel-related artery potency (Thrombolysis in Myocardial
Infarction [TIMII grade 2 or 3 flow) was observed In 40 of 53
patients at 60 min (75 .5%, 95% confidence interval [CI[ 61% to
64%) and in 55 of 60 patients at 90 min (91
.7%, 95% Cl 80% to
95%) after the rt-PA bolus. By 90 min the majority of patients
(55%) exhibited TIMI grade 3 flow ; infarct artery patency at
120 min was 84,9%
.
During hospitalization definite recurrent ischemia occurred in
nine patients (15%) ; nonfatal recurrent infraction was noted in
one 11 .7%). Four patients (6.7%) experienced major bleeding,
including one with intracranial bleeding
. There were seven deaths
When administered to selected patients with acute myocar-
dial infarction, thrombolytic therapy has been shown to
decrease mortality and improve left ventricular function
(1-4) . The proposed mechanism for these salutary effects is
restoration of coronary artery blood flow (5,6). Thus, in
assessing the value of a thrombolytic agent or regimen
patency of the infarct-related artery is an important consid-
eration .
In addition, there is an inverse relation between efficacy
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(11,7%), Mortality was significantly Influenced by the occurrence
of cardiogenic shock, which was present in five patients at the time
of enrollment.
Blood fibrinogen levels were obtained before and during rt-PA
infusion. At baseline and 30 and 150 min after the bolus dose, the
mean fibrinogen level (± SD) was 284,83 ± 77,39, 237 .96 * 76 .92
and 192 .04 ± 57 .82 mg/dl, respectively . Compared with the
baseline value, there was a significant Ip < 0.05) decrease in
fibrinogen al both 30 and 150 min .
Thus, a new regimen of intravenous rt-PA has been identified
that is logistically well suited for both pee- and in-hospital
treatment of patients with acute myocardial infaretioa . The
regimen features an initial 20-mg bolus dose and is capable of
achieving infarct artery patency rates in excess of 90%, 90 min
after initiation of therapy . Clinical use of this regimen shoa .d he
deferred until the incidence of associated major adverse events Is
determined in a prospective large scale controlled trial
.
(J Am Cell Cardiol 1991 ;18:1774-8)
and the elapsed time from the onset of acute myocardial
infarction to drug administration, such that the greatest
benefit of thrombolytic therapy is derived when treatment
occurs early in the course of infarction (2,7) . This relation
has served as a rationale to develop programs for prehospital
administration of thrombolytic agents .
Of the available thrombolytic agents, recombinant tissue-
type plasminogen activator (rt-PA) has been shown to be
superior in achieving reperfusion (8) . However, the logistics
of typical dosing regimens of el-PA employing a prolonged
continuous intravenous infusion are not optimal for prehos-
pital nse . The ideal thrombolytic regimen for prehospital use
would employ a bolus injection of the drug . Moreover, an
agent with a short half-life would be advantageous in the
prehospital setting to avoid commitment to a prolonged lyric
state in the event of inappropriate patient selection, Accord-
ingly, we developed a new dosing regimen of rI-PA for
patients with acute myocardial infarction that was designed
for prehospital use . The regimen consists of an initial 20-mg
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bolus injection to initiate thrombolysis . followed by a 30-min
delay to allow patient transport, after which 80 mg is infused
over 2 h . The total dose administered is 100 mg over 2 .5 h .
To test the safety and efficacy of this regimen
. we
performed an open label angiographic trial . the Prehospital
Administration of rt-PA Study (PATS) Phase 1
. The primary
end point of this investigation was the proportion of patent
infarct-related coronary arteries 90 min after rt-PA
:,dminis-
tration .
Methods
Study patients . Patients presenting to the hospital emery
gency department with suspected acute myocardial infarc-
tion within 6 h of symptom onset were considered as
potential subjects for this trial . Inclusion criteria for patient
eligibility were I) age 18 to 75 years, 2) duration of infarct
symptoms 0 .5 to 6 h, and 3) new ST segment elevation of at
least 0.1 mV present in two or more contiguous electrocar-
diographic (ECG) leads
. Exclusion criteria were I) any
contraindications to thrombolytic therapy, 21 inability or
refusal to provide informed consent. 3) the presence of
advanced or terminal illness, 4) a history of coronary artery
bypass surgery, 5) a history of percutaneous transluminal
coronary angioplasty within 6 months, and 6) the infusion of
any thrombolytic agent for myocardial infarction within 2
weeks.
Study design and protocol. Once informed consent was
obtained, patients received the rt-PA regimen consisting of
an initial 20-mg intravenous bolus injection and . 30 min later .
a 6-mg intravenous bolus injection followed immediately by
a 2-h infusion at a rate of 54 mg over hour I and 20 mg over
hour 2 . Immediately after the initial rt-PA bolus injection,
heparin (5,01)0 U intravenously) was administered . This was
followed I h later by a constant 1 .00 -Ulh infusion of heparin
adjusted to the partial thromboplastin time and maintained
for5 days . Each patient also received intravenous lidocaine .
Within 12 h of enrollment, treatment with aspirin (80 mg
orally once daily) and a calcium channel blocking agent,
usually nifedipine, was started .
In each patient seria, coronary angiography was per-
formed as soon as possible after the initial rt-PA bolus dose .
Whenever feasible, the status of the infarct-related artery
was assessed at 30, 60, 90 and 120 min after the bolus dose .
Coronary flow was evaluated according to the Thoombolysis
in Myocardial Infarction (TIMI) flow scoring system (9) .
Percent stenosis was measured by electronic caliper tech-
nique. Ait infarct-related artery was considered to be patent
if TIMI grade 2 or 3 flow was present . Each cineangiogram
was evaluated at least twice by two independent investiga-
tors (G .R.M ., B .L.S.). Discrepancies in interpretation were
adjudicated by a third investigator (D.O .W .) .
The primary end point oJthis trial was the proportion of
infarct-related arteries that were patent at 90 min . Secondary
end points included the predischarge met . -..e of recurrent
ischemia, recurrent infarction, death, bleeding complica-
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Lions, stroke and the need for coronary revascularization .
Blood sampling was obtained to measure fractional creative
kinasc . prothrombin time and partial thromboplastin time .
Fibrinogen was measured by a modified Clauss method (10) .
The need for additional treatments, tests or procedures was
determined by conventional clinical guidelines .
This protocci was approved by the Center for Biologics
Evaluation and Research, Food and Drug Administration as
well as by the Institutional Review Board of both participat-
ing hospitals .
Statistics . Quantitative measurements are expressed as
mean values SD . Repeated measures analysis of variance
was performed on fibrinogen levels . A p value < 0.05 was
considered significant.
Results
F+deatcharacteristics(Tablel). Sixty-three patients with
suspected acute myocardial infarction were entered into this
trial . Of this group. two were excluded from analysis for
failure to meet entry ECG criteria after strict review, and
one was excluded because of a diagnosis of myocarditis . The
excluded patients did not demonstrate serum enzyme after-
ations indicative of acute myocardial infarction . The final
study cohort consisted of 60consecutive consenting patients
with documented acute myocardial infarction enrolled at the
Rhode Island and Bellevue Hospitals between January 1989
and January 1990.
Baseline
character
sties
of the study group are shown in
Table 1 . Eighty percent of the patients were male. There was
a low prevalence of previous myocardial infarction (13 .3%),
prior angina (10%) or unstable angina (6.7%) . The average
age was 55.2 ± 11 .3 years. The mean time to rt-PA treatment
from symptom onset was 166.7 ± 79
.9 min
. Infarct location
was anterior in 38.3%, inferior in 46.7% and other in 15% .
The infarct-related artery was identifiable in each patient ; it
was the left anterior 'ascending coronary artery in 25
patients (41 .7%) . the right coronary artery in 24 (40%) and
the left circumflex coronary artery in I1 (18 .3%; . The peak
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Figure] . A, Cumulative administered dose over time of recombinant
tissue-type plasminogen activator in PA) with the earnest egimen
in 60 patients. Treatment was initiated with a 20-mg bolus dose and .
after a 30-min delay . 80 mg was infused over 2 h . B, The infarct-
related artery IIRA) potency rate at 30 . 60
. 90
and 120 min after the
bolus dose. Closed circles represent the proponin, of patients with
inf rct-related artery pa2mcv at the given lime period. Brackets
represent 95% confidence intervals .
serum creatine kinase level was 2 .624 ± 1 .879 IU/liter: the
average time to a peak level was 13 *- 13 .3 h .
Coronary angiography (Fig. 1) . Of the 60 patients . 20
arrived in the cardiac catheterization laboratory in time for
an angiogram 30 min after the 20-mg rt-PA bolus injection .
Fifty-three patients had an angiogram at 60 min after injec-
tion, all 60 had an angiogram at 90 min and 53 had an
angiogram at 120 min . The patex0y rate at 30 . 60, 90 and
120 min was 50% . 75 .5%, 91 .7% and 84
.9%, respectively .
The 95% confidence intervals for these determinations are
26% to 561 . 61 to 84%, g0% to 9517c and 71% to 91% .
respectively . At 90 min, 33 patients (55%) had TIMI grade 3
How . 22 (36 .6%) had TIMI grade 2 flow and 5 (8.3%) had
TIM[ grade I or
o
flow
. Thus, the potency rate at 90 min, the
primary end point of this study, was 91 .7% with a 95%
confidence interval of 80% to 95% . The percent diameter
reduction of the infarct-related stenosis at 30 . 60 . 90 and
120 min was 91 .3 t 10
.2
. 79.5 * 17.2 . 73 .1 ± 20.2 and 72
.3
t 19
.], respectively .
Follow-up uutgiogntphv
before hospim( discharge was
performed in 26 patients an average of 9 ± 2 .4 days after the
initial angiogram. Predischarge angiography was not part of
the initial protocol but was performed when feasiib`le . The
infarct-related artery was patent with TIMI grade 3 flow in 22
patients (84
.6%) and TIMI grade 2 flow in 4 )15.4%).
Clinical events in the hospital (Table 2) . Fourteen patients
(23
.3%) had chest pain suggestive of recurrent ischemia
during the hospital slay. Of these, nine (15%) had definite
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Table 2. Clinical Events in 60 Patients From Initial Therapy
Through Hospital Discharge
Cull = cardiac eathelerieation
: CVA = eerehravascular accident : EM =
ekctreneclotical .
ischemia ; that is, chest pain associated with new ECG ST-T
wave changes. Five patients (8.3%) had possible ischemia .
defined as chest pain without definite ECG changes. There
was a single (1 .7%) nonfatal reinfaectidn. Six patients (1(
17,1
developed cardiogenic shock during the hospital period : five
of these had shock al the time of enrollment . One patient
0
.7%) had a nonhemorrhegic embolic stroke during angiog-
raphy in the acute phase of infarction . Seven patients
(11 .7%) died
. The cause of death was related to cardiugenic
shock in three patients (5%). One death was due to recurrent
infarction, one to sudden electromechanical dissociation,
one to complications of intracranial bleeding, and one to
acute pulmonary edema .
Coronary artery bypass graft surgery was carried out in
four patients 16 .7701 and was performed electively in each . A
single patie: had a left ventricular aneurysmeclomy . Twen-
ty-six patients (43370) underwent coronary angioplasty be-
fore hospital discharge. Sixteen (26.6%) of these procedures
were elective; 14 were performed for recurrent ischemia and
2 were performed in asymptomatic patients. An additional 10
patients (16.7%) underwent coronary angioplasty at the time
of angiography performed during the acute phase of infarc-
tion after potency determination at 90 min. Coronary angie-
plasty was performed in this group as a rescue procedure for
failure of the infarct-related artery to open in four patients .
because of decreased TIMI flow grade in four patients and
according to physician discretion in two others .
Nn.
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Minor bleeding occurred in 13 patient, 121,7x1 . This
included a small hematoma at the catheredzation ,it, in
seven patients (11 .794) . an additional six patient, il(Wi1
developed hematuria during the hospital course . Major
bleeding (defined as either life-threatening bleeding. a
>3 gldl decrease in hemoglobin or blood loss requiring a
blood transfusion) occurred is four patients (6 .7`41 . Intm-
cranial bleeding occurred in a 65-year old woman who had
been found on the floor at home before hospital arrival .
Retrospectively, head trauma could not be ruled out in this
patient
. One patient had retroperitoncal bleeding and too
patients developed a major hemaloma at the catheterizati in
site . Two patients required blood transfusion .
Fihrinngett lereiv were obtained in 24 patients before ,end
during rt-PA infusion. At baseline and 30 and 150 min of er
the 20-mg bolus injection- the mean I SD) fibrinogen le,el
was 284.8 -- 77,4 . 238 '- 77 and 192 c 57 .8 mgldl, respec-
tively . Compared with the baseline value, there was a
statistically significant decrease in fibrinogen at both 30 and
150 min (p < 0 .00011. However, the magnitude of the
decrease was greater at 150 min (32.61.) than at 30 min
(16
.5%) .
Discussion
Patency rules. This trial evaluated a new regimen at
rt-PA administration designed to facilitate thrombolysis for
prehospital use . The goal of the study was to determine
whether this new regimen is an adequate replacement for the
extensively tested conventional regimens . Infarct-related
artery patency at 90 min was considered a worthy end point
of efficacy because reperfusion is the proposed mechanism
by which salutary effects
of thromholytic h-rapy are
achieved. The 90-min patency rate of 91 .75: ub,crv d in this
trial not only equals but exceeds the rates of 61'7 to 79rf
reported for other regimens (I1-14)
. Verstraete et al. I I I I
reported a 61h patency rate in 62 patients who received
0.75 mgikg body weight of n-PA over 90 min ; the rt-PA used
in that trial, however, was produced in cell culture by roller
bottle methodology. The Thrombolysis and Angioplasty in
Myocardial Infarction ITAMII study group (12) reported a
75% 90-min patency rate using a total dose of 150 mg with a
maximal 9-mg bolus injection and a 6- to 8-h infusion, The
same investigators (13) also reported n 9(1-mm patency rate
of 79% using a weight-adjusted regimen of 1,5 mglkg infused
over 4 h . Using a 1(M)-mg dosing regimen with a 6-mg initial
bolus injection followed by a 6-h infusion, the TIMI-ttA
investigators (141 reported a 757 palency rate at an average
time of 1 .4 ± 0.4 h after initiation of rt-PA administration.
More recently . other new regimens have been reported
which demonstrate the ability to achieve higher 90-min
patency rates. Neuhaus et al . 1151. using a IS-mg bolus dose
and an 85-mg infusion over 911 min, reported a 9)) Vr palency
rate at 90 min in 74 patients, Smaller, e( al . (16), in a study
company.;
. weight-adjusted rapid rt-PA Infusion with stan-
dard dosing, reported a'Rl-min paten :, rage of 84 4 in 84
stckrvitsi i FT At
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patients receiving a total of
2_ mg kg of rt-PA over 3 h. In this
regimen . L'_ mg kg
w
give. over the 1st h with In`i
tmaxmmal 10 mat) a a bolus injection . By contrast, in the
standard group ( 1,25 mgikg for 3 h; 0_71 mskg over the
I st h . Ill' as a bolus) the 90-min palency rate was 70'4
in 91
patients
.
hleciianisms of improved patency. Although the mecha-
nism by which these high patency rates are achieved is
uncertain, some investigators (I5-171 have suggested that
the patency rate is linearly related to the total administered
dose so that higher rates occur when more drug is infused .
With standard regimens
. 70 mg of drug is delivered at 9(Tmin .
but by 90 min Neuhaus et a1 . ( Iti infused 100 mg of rt-PA .
whereas Smalli, ., et al . IIF) a raged 118,4 in, . However,
with the PATS dosage reported herein only 80 mg of drug
was infused b
: 90 min when the patency rate was 91 .751
IFig . I). This observation suggests that the total adminis-
tered dose . ,June, may not be responsible for enhanced
patency .
:1n ~Ihrr7l~nire e .rplamuion ur he considered its thin a
I. .. ..tint,) Sifts dose rr up uu,ernent patency. Recently', in
series :.f 20 patients, Tehbe et al . 118) reported a 7571
fill-min patency rate using a single 50-mg bolus injection of
rl-PA . Similarly . Tranchesi iii al . (191 reported a 72% 60-min
recanalization rate in 2_5 patients who received only a ?0-mg
bolus injection . Furthermore, in an experimental preparation
C(h, a higher rate of thrombolysis as ui-scrved after bolus
administration of rt-PA compared with continuous infusion
of the same dose . These preliminary studies coupled with the
present report support the concept that a higher initial bolus
dose may enhance reperfusion . Moreover, (he 5044 patency
rate and 16 .x4 1 decrease in plasma fibrinogen observed at
9) min suggest that the 20-mg bolus dose alone has throm-
bulytic action.
Complications. The improved rt-PA patency observed in
this study did not appear to he at the expense of excessive
complications . 7'he incidence of recurrent infarction 0 .7i).
recurrent dednte ischemia
(15r',) and Needing (28.3`4) are
similar to those in previous report, (8) . although the small
number of patients in this study does not permit definitive
comparisons. The mortality rate in this study (11 .7%) was
significantly influenced by the large number of patients 11094 )
with cardiogenic shock. A larger experience will he Feces-
,at), (o determine the precise incidence of clinical events
,us
. .ocia(ed with this regimen
.
Role of coronary angiography . The role of serial angiog-
raphy performed in this trial as an influence on infarct-
related artery patency needs to he addressed . Repeated
coronary injections with contrast medium could have a
hydraulic effect in disrupting occlusive thrombus . This trial
was not designed to answer this question, but the lower
patency rate at 120 min 184
.9911 compared with that a( 9(1 min
(91 .7k) does not support this contention . Additional evi-
dence for lack of a significant contribution of serial angiog-
raphy in attaining patency comes from the Mt . Sinai-New
York University Reperfusion Trial (2U, in which serial
l7-/8
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-iziog, . n : p nthout tylic agents resulted in only a 6%
oral-tien rdc a IS patients !reared with nitroglycerin .
Clinical utility . Aside from improved palercy . this dusing
regimen has other attractive features . Firt. it is well suited
for the log,stics atptchospital administration
. : reparation is
simple and should not encumber patient transport . The
potential benefit derived from prehospital administration is
I ., decrease the elapsed time from symptom onset to treat-
ment a large component of which occurs after hospital
arrival 122 . 2 33 .
Second . there are m-hospital situations where this regi-
ten may has, practical value
. Current practice in many
institu:ioni is to dcla~ thrombolytic therapy until after the
patient has been evaluated by a cardiologist or transferred to
a specialized coronary care unit. This regimen should allow
others to initiate in-hospital treatment earlier with the 20-mg
bolus
and the 30-min delay used for infusion preparation,
patient transport or reassessmettt by specialists who may rot
be immedtaiety available .
Conclusions- A new regimen of intravenous rt-RA has
bean identified that is logistically well suited for both pie ,
and in-hospital treatment of patients with acute myocardial
infarction.
The regimen is
capable of achieving patency rates
in excess of
90%, Precise determination of the incidence of
clinical events associated with this regimen and the value
of
this regimen in relation to that
of other regimens already
employed will require direct randomized comparison in a
larger group of patients . Clinical use of this regimen should
be deferred until the incidence of associated major adverse
events is determined in such prospective larger
scale con-
trolled
trials
.
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